Skip to main content
Signal8

de Boer Daniel Anton

SEC insider (Form 3/4/5 filer). CIK 0002117546. Chief Executive Officer at ProQR Therapeutics N.V. (PRQR). 3 reported Form 4/5 transactions since Sep 2024; latest on Jul 31, 2026. Located in LEIDEN.

Companies de Boer Daniel Anton has filed insider reports for

  • ProQR Therapeutics N.V. (PRQR): Director, Officer, Chief Executive Officer
de Boer Daniel Anton profile photo

de Boer Daniel Anton

CIK: 0002117546

Transaction Breakdown

Open Market Buys (P)3 (100.0%)

High conviction signal

Open Market Sales (S)0 (0.0%)

Position reduction

Option Exercises (M)0 (0.0%)

Derivative conversions

Awards (A)0 (0.0%)

Compensation grants

Other (G, F, J, C, D, …)0 (0.0%)

Gifts, tax withholding, conversions, dispositions to the issuer and other codes

Companies & Roles (1)

ProQR Therapeutics N.V. logo
PRQR

ProQR Therapeutics N.V.

DirectorOfficer

Discretionary Trading P&L

Holdings

Transaction History (3 total)

  • ProQR Therapeutics N.V. logo
    PRQR

    ProQR Therapeutics N.V.

    Jul 31, 2026
    Purchase
    Direct
    200K shares at avg. $1.77$354K
  • ProQR Therapeutics N.V. logo
    PRQR

    ProQR Therapeutics N.V.

    Jul 9, 2026
    Purchase
    Direct
    150K shares at avg. $1.74$261K
  • ProQR Therapeutics N.V. logo
    PRQR

    ProQR Therapeutics N.V.

    Jul 7, 2026
    Purchase
    Direct
    150K shares at avg. $1.59$239K

1-3 of 3